Clinical Scorecard: Co-infection with influenza A(H1N1) and A(H3N2) correlates with increased hypoxemia, fungal co-infections, and negative short-term outcomes in adults suffering from influenza-related community-acquired pneumonia

At a Glance

Key Highlights

• The study compared 51 H1N1 mono-positive patients with 46 H1N1/H3N2 dual-positive patients.

• Dual-positive patients had lower PaO2/FiO2 and higher C-reactive protein and interleukin-6 levels.

• Invasive mechanical ventilation occurred in 23.9% of dual-positive patients and 7.8% of mono-positive patients.

• Fungal co-detection was more frequent with dual positivity (47.8% vs 25.5%), driven primarily by Pneumocystis jirovecii detection.

• Composite adverse hospital disposition occurred in 26.1% versus 3.9% of patients.

• Dual positivity indicated co-detection during the same admission, not confirmed simultaneous coinfection.

Guideline-Based Recommendations

This retrospective study did not establish new guidelines for diagnosing or managing influenza-associated CAP.

Diagnosis

• Influenza A positivity was established from throat-swab specimens using real-time quantitative RT-PCR.

• Subtype classification was based on laboratory records indicating A(H1N1)pdm09 and A(H3N2) positivity.

• BALF targeted next-generation sequencing provided broad bacterial, fungal, and viral co-detection.

• Detected organisms were not automatically considered evidence of clinically significant or invasive infection.

Management

• The findings support cautious, oxygenation-centered assessment of adults with influenza-associated CAP.

• Dual-positive patients may warrant heightened microbiological vigilance because fungal co-detection was more frequent.

• The study did not evaluate specific antiviral, antimicrobial, or antifungal treatment strategies.

• Dual positivity should not be interpreted as proof that simultaneous infection caused greater severity.

Monitoring & Follow-up

• Assess oxygenation because PaO2/FiO2 was the principal clinical correlate of excess risk.

• Consider inflammatory markers and the need for invasive mechanical ventilation when evaluating severity.

• Interpret fungal detections cautiously because validated invasive-disease classifications were unavailable.

• The study did not include postdischarge vital-status follow-up.

Risks

• Dual positivity was associated with worse hypoxemia, more invasive ventilation, and a higher frequency of adverse hospital disposition.

• In-hospital mortality was numerically higher with dual positivity, but the difference was not statistically significant.

• P jirovecii detection may represent low-burden carriage rather than pneumonia.

• Pre-BALF corticosteroid exposure, host factors, and differences in sampling timing may have confounded pathogen co-detection and outcomes.

Patient & Prescribing Data

The cohort included 97 adults hospitalized with influenza-associated CAP: 51 with H1N1 mono-positivity and 46 with H1N1/H3N2 dual positivity. No H3N2 mono-positive comparison group was available.

The study recorded pre-BALF systemic corticosteroid exposure but did not provide reliable antiviral-timing data or evaluate treatment efficacy.

Clinical Best Practices

• Interpret H1N1/H3N2 dual positivity as virologic co-detection rather than confirmed simultaneous coinfection.

• Prioritize oxygenation when assessing clinical risk.

• Interpret BALF sequencing results in their clinical context rather than equating detection with invasive disease.

• Distinguish composite adverse hospital disposition from mortality because the composite included discharge against medical advice.

• Apply the findings cautiously because this was a small, single-center, hypothesis-generating study.

Related Resources & Content

Dual-Subtype Positivity of Influenza A(H1N1) and A(H3N2) Is Associated With Worse Hypoxemia, Fungal Co-Detection, and Adverse Short-Term Outcomes in Adults With Influenza-Associated Community-Acquired Pneumonia — Li Q, Li H, Fan L, et al. International Journal of Infectious Diseases. 2026;171:108985. doi:10.1016/j.ijid.2026.108985.